Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2007

View Archived Issues

New generation of MRI contrast agents developed at Bracco

Assessing the efficacy of new drugs for multiple sclerosis in clinical trials: I

Preclinical neuroprotective effects of statins reported in AD and stroke models

Positive results from preclinical pharmacokinetic testing of ANX-514

Insmed provides overview of pipeline

Enrollment completed in study comparing drug-eluting stents to cardiac surgery

Preclinical antitumor profile of Serono's Aurora kinase inhibitor AS-703569

Novel JAK2/FLT3 inhibitor shows promise for the treatment of myeloproliferative disorders

Mycobacterium cell wall preparation shows promise as a novel cancer immunotherapy

Studies reveal topical activity of amitriptyline/ketamine cream

Clinical results for MPC-7869, CERE-110 in Alzheimer's disease reported

New agents for treating Alzheimer's disease disclosed in recent Myriad patent

Recent patents describe new antidiabetic agents

Roche's research initiatives for Tamiflu

Phase II trials planned for VQD-002

Sangamo licenses ZFP technology to Genentech

Enrollment on track in phase IIa study of SC-12267 for RA

New phase I trial studies EP-1233 and MVA-BN Polytope in combination

Medivir reports significant events of first quarter

Chugai reviews domestic developments of first quarter

Recent patents report novel agents for HIV infection

Vardenafil begins phase II study in patients with BPH / News in Context

Treatment begins in pivotal study of picoplatin for SCLC

New phase IIb trial studies Aastrom's TRCs in critical limb ischemia

Response submitted to approvable letter for nebivolol

FDA Advisory Committee reviews Advair Diskus 500/50 sNDA

Factive approved for five-day treatment of CAP

New FDA approval for Humate-P

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...